European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.
Each quarterly edition examines areas of importance – both economic and technical – to contract research organisations, contract manufacturers, regulatory controllers, consultants and analysts. This enables regulatory bodies to link directly with policy-makers both in major contractor groups and pharmaceutical companies, and thereby convey regulatory information directly from the governing bodies, but also ensure debate between the policy-makers and consultancy groups.
Dr Graham Hughes,
Published quarterly in
September and December
17-18 November 2015, Hilton Barcelona, Barcelona
InForm Europe 2015 is the leading
pharma event for decision makers working in formulation and pre formulation
across Europe, that meets the needs of an industry that is set to rise to $224
billion in 2017 More info >>
LONDON, UK (GlobalData), 11 March 2015 - The steady decline in new Ebola
cases presents a formidable challenge to current and future clinical
trials of investigational treatments for the disease, as it will be more
difficult to recruit study participants and demonstrate efficacy, says
an analyst with research and consulting firm GlobalData. More info >>
Shipping with Active Packaging Containers: Three Pre-flight Decisions that Impact the Success of High-value Global Shipments
It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?
More info >>